Charles River Laboratories International CRL · USD
Health Care · Life Sciences Tools & Services · US listing · 🇺🇸 United States
S&P 500
353.34
+4.69%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Charles River Laboratories International
From its filings with the US Securities and Exchange Commission
Charles River Laboratories International is based in Wilmington, Massachusetts. Its shares trade on NYSE under the ticker CRL. It is a member of the S&P 500. The SEC classifies its business as commercial physical & biological research. In the fiscal year to 27 December 2025, it reported revenue of $4.02bn and a net loss of $144.3m. At that date it held total assets of $7.14bn and shareholders' equity of $3.16bn. By business, Service brought in 80.9% of revenue, followed by Product at 19.1%. By region, U.S. accounted for 53.3%, followed by Europe at 27.5% and Canada at 12.5%.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 23 Jun 2000
- Employees
- 19,700
- Website
- criver.com ↗
- Head office
- 251 BALLARDVALE ST, WILMINGTON, MA, 01887
- Classification
- Services-Commercial Physical & Biological Research
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Mark EnyedyIndependent Director
- Mr. Paul GravesIndependent Director
- Mr. James FosterChairman of the Board, President, Chief Executive Officer, since 1976$13.5m
- Mr. Michael KnellInterim Chief Financial Officer
- Ms. Birgit GirshickChief Operating Officer, Corporate Executive Vice President$5.1m
- Ms. Victoria CreamerCorporate Executive Vice President, Chief People Officer$2.8m
- Mr. Joseph LaPlumeCorporate Executive Vice President - Corporate Development and Strategy$3.0m
- Ms. Shannon ParisottoCorporate Executive Vice President - Discovery and Safety Assessment Management
- Dr. Martin MackayLead Independent Director$340,500
- Dr. Nancy AndrewsIndependent Director$340,500
- Mr. Steven BargIndependent Director
- Mr. Abraham CeesayIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 73
- Environment
- 74
- Social
- 79
- Governance
- 66
- Direct emissions (scope 1)
- 85,724 t
- Energy emissions (scope 2)
- 99,891 t
- Value chain emissions (scope 3)
- 435,589 t
- Women in the workforce
- 59.8%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Charles River Laboratories International Inc has established itself as a prominent player in the research and development services industry.
- Strong financial performance and consistent revenue growth provide a solid foundation for future expansion and investment.
- The company possesses a wide range of capabilities and expertise, offering a comprehensive suite of services to its clients.
- Strong reputation and long-standing relationships with key industry partners contribute to a highly trusted brand image.
Weaknesses
- Charles River Laboratories International Inc may face potential challenges in integrating newly acquired companies and maintaining consistent quality standards across all operations.
- Reliance on a few major clients for a significant portion of revenue could pose a risk to the company's financial stability in case of client attrition.
- Limited geographical presence may hinder the company's ability to tap into emerging markets and expand its client base.
- The company might face regulatory constraints and compliance issues in the highly regulated industries it serves, increasing operational complexity.
Opportunities
- Increasing demand for outsourcing in the pharmaceutical and biotechnology sectors opens up new growth opportunities for Charles River Laboratories International Inc.
- Expansion into untapped markets, such as Asia and Latin America, could lead to additional revenue streams and diversification.
- Advances in technology and innovation present the opportunity for the company to enhance its services and offer cutting-edge solutions to clients.
- Strategic partnerships and collaborations with academic institutions and research organizations can foster innovation and strengthen the company's position in the market.
Threats
- Intense competition from other contract research organizations may lead to pricing pressures and reduced market share.
- Evolving regulatory landscape and potential changes in government policies could impact the company's operations and profitability.
- Economic downturns and fluctuations in research and development budgets of pharmaceutical companies could affect demand for Charles River Laboratories International Inc's services.
- Increasing scrutiny on animal testing practices may result in stricter regulations and a potential shift towards alternative testing methods.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.